The numbers, as of May 25
- 25 US GLP-1 telehealth programs tracked.
- $25/mo the cheapest all-in cash-pay total (Hone Health).
- $178/mo the median all-in cash-pay total across all programs.
- $498/mo the most expensive all-in cash-pay total (Lindora).
- 19.9x the price ratio between cheapest and most expensive.
- ~3x the per-mg cost premium for brand Wegovy vs compounded semaglutide at the same 2.4 mg/week maintenance dose.
- ~7x the per-mg cost premium for brand Ozempic (cash-pay, no diabetes diagnosis) vs compounded semaglutide.
See the full Q2 2026 Price Index for the underlying per-program breakdown and unit-economics analysis.
Quotable sentences, ready to paste
Cite as: GLP Chart, glpchart.com, or with the specific URL.
“The 19.9x spread between the cheapest and most expensive US GLP-1 telehealth programs is the largest in any healthcare-comparison category we have indexed,” according to GLP Chart's quarterly price index.
“Compounded semaglutide costs $10-$26 per milligram at maintenance dose, roughly one-third the per-mg price of brand Wegovy through NovoCare and one-seventh the per-mg price of brand Ozempic cash-pay, according to GLP Chart's Q2 2026 unit-economics analysis.”
“Insurance with prior authorization can reduce GLP-1 patient cost to $25-$50/month, but the PA process denies an estimated 30-40% of initial applications and adds 4-8 weeks to onboarding,” GLP Chart reports.
Topics we can speak to on background
- The economics of compounded GLP-1. Why the supply moved off the shortage list, how 503A pharmacies have adapted, what the “personalized formulation” trend means in 2026.
- Insurance prior-authorization mechanics. The four documented criteria, the appeal pathways, the denial rate by carrier when available.
- Wegovy vs Zepbound efficacy. Trial-versus-real-world adherence, dose-response curves, the dropout problem in both registration trials.
- Maintenance dosing and discontinuation. What happens when patients stop, the regain curve, what the pharmaceutical industry is and is not saying about lifetime use.
- Regulatory shifts. The FTC consumer-protection lens on compounded GLP-1 marketing, state pharmacy-board enforcement, the patent-cliff timeline for the next generation of incretins.
- Telehealth program differentiation. Which models work, which are racing to the bottom on price, which are quietly upselling into supplements and coaching.
Who we are
GLP Chart is an independent editorial comparison site, not a telehealth program, not a pharmacy, not a consultancy. We do not accept paid placement; we are funded by affiliate commissions on outbound clicks (disclosed on every page). We do not let programs approve our content before publication.
Editor: John Samaras. Based in Austin, Texas. Full-time on the category since 2026. Prior background in consumer-product analysis and SaaS. See the full About page and our scoring methodology.
Contact for press
Email: press@glpchart.com. Response within 24 hours on business days. For source documents (purchase-flow screenshots, manufacturer pricing pages, 503A pharmacy invoices, patient-survey raw data), include the specific stat or claim you are sourcing and we will send the underlying file.
Embargoed access:the next quarter's Price Index publishes on the first Monday of each quarter. Email at least 72 hours in advance for embargoed pre-release.
Recent coverage
GLP Chart launched publicly in early 2026. Our coverage list is still small and built honestly. If you're a journalist who has cited our data and you'd like your outlet listed here, email press@glpchart.com with the article URL and we'll add it.
What you can expect: each citation listed with outlet logo, article title, publication date and a direct link. We do not list paid placements; we have none.
Press kit and brand assets
Direct downloads, no email required. Reuse with attribution and a link back to glpchart.com.
Brand colors: burnt orange #C7522A (fills), burnt orange dark #B04420(text + links), bone white #F5F1E8 (background). Type pairing: Source Serif 4 (display) + Geist (body). For the full style sheet, view the live methodology page source.
